PubRank

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)

Clinical Trial ID NCT01188187

PubWeight™ 23.37‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01188187

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
2 First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013 1.57
3 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
4 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014 1.11
5 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
6 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
7 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
8 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
9 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
10 Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol 2012 0.91
11 The role of heat shock proteins in bladder cancer. Nat Rev Urol 2013 0.91
12 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
13 Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl 2014 0.88
14 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
15 Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol 2013 0.87
16 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
17 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
18 Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014 0.80
19 Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Med 2013 0.80
20 Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol 2014 0.79
21 Potential use of custirsen to treat prostate cancer. Onco Targets Ther 2013 0.78
22 Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer 2014 0.77
23 Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer. Asian J Androl 2014 0.77
24 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
25 Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol 2015 0.75
Next 100